11:47 AM EDT, 06/03/2025 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday that nearly one-third of heavily pretreated relapsed or refractory multiple myeloma patients who received a single infusion of Carvykti, or ciltacabtagene autoleucel, remained progression-free for five years or more with no maintenance or subsequent myeloma treatment.

The new long-term results are from the Cartitude-1 study, which enrolled 97 patients, according to the company.

Legend Biotech ( LEGN ) said that at a median follow-up of 61.3 months, median overall survival was 60.7 months and 32 patients remained progression-free for more than five years.

Safety signals were consistent with Carvykti's profile and no new movement or adverse events were reported, while two new cases of second primary malignancies were observed, the company said.

Shares of the company were down 3.2% in recent trading.

Price: 28.38, Change: -0.94, Percent Change: -3.21